November 16, 2016Open Access
View Full PaperECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
Key Points
Key points are not available for this paper at this time.
Abstract
sponsorship: SD has served as a speaker, consultant, and advisory board member for Schering-Plough, Abbott Laboratories, Merck, UCB-pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Danone, Alpha Wasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor, and Johnson Speakers fees from Abbvie, Boehringer-Ingelheim, Chiesi, Falk, Ferring, Janssen, Mitsubishi Tanabe, MSD, Takeda, Tillotts, Zeria; Consultancy fees from: Abbvie, Boehringer-Ingelheim, Ferring, Janssen, MSD. (AbbVie, MSD, Pfizer/Hospira, Takeda, Boehringer-Ingelheim, Chiesi, Falk, Ferring, Janssen, Mitsubishi Tanabe, Tillotts, Zeria)